Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00861705 · OUTCOME

Pathologic Complete Response (pCR) in the Breast and Axilla. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is) Plus the Absence of Any Tumor Deposit >0.2 mm in Sampled Axillary Nodes (ypT0/isN0).

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery · Source last updated 2026-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants with pCR
Interval / dispersion
95% Confidence Interval
Time frame
At the time of definitive surgical removal, up to 28 weeks

What was measured

Comparing regimens that contain bevacizumab (arms 2\&4) versus not (arms 1\&3).

Groups in this outcome

Factor B: Bevacizumab

Factor B is the addition or not of bevacizumab: the experimental regimens included bevacizumab (Arms 2 \& 4).

Factor B: No Bevacizumab

Factor B is the addition or not of bevacizumab: the control regimens did not include bevacizumab (Arms 1 \& 3)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Factor B: Bevacizumab215
Factor B: No Bevacizumab218

Reported measurements

Source class 1
Values in percentage of participants with pCR · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Factor B: Bevacizumab52Not reported4558Not reported
Factor B: No Bevacizumab44Not reported3851Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    p Value
    0.057
    statistical Comment
    Reported p-values are unadjusted and 1-sided
    statistical Method
    Chi-squared
Complete source fields
analyses
  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    p Value
    0.057
    statistical Comment
    Reported p-values are unadjusted and 1-sided
    statistical Method
    Chi-squared
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        45
        upper Limit
        58
        value
        52
      2. group Id
        OG001
        lower Limit
        38
        upper Limit
        51
        value
        44
denoms
  1. counts
    1. group Id
      OG000
      value
      215
    2. group Id
      OG001
      value
      218
    units
    Participants
description
Comparing regimens that contain bevacizumab (arms 2\&4) versus not (arms 1\&3).
dispersion Type
95% Confidence Interval
groups
  1. description
    Factor B is the addition or not of bevacizumab: the experimental regimens included bevacizumab (Arms 2 \& 4).
    id
    OG000
    title
    Factor B: Bevacizumab
  2. description
    Factor B is the addition or not of bevacizumab: the control regimens did not include bevacizumab (Arms 1 \& 3)
    id
    OG001
    title
    Factor B: No Bevacizumab
param Type
NUMBER
reporting Status
POSTED
time Frame
At the time of definitive surgical removal, up to 28 weeks
title
Pathologic Complete Response (pCR) in the Breast and Axilla. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is) Plus the Absence of Any Tumor Deposit >0.2 mm in Sampled Axillary Nodes (ypT0/isN0).
type
SECONDARY
unit Of Measure
percentage of participants with pCR

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice